Skip to main content
. 2022 Mar 3;10:828916. doi: 10.3389/fcell.2022.828916

FIGURE 1.

FIGURE 1

Expression of inhibitory Siglecs on human tumor-infiltrating DCs. (A) Representative examples of Siglec receptor expression determined by flow cytometry on different cDC subsets from primary patient samples. (B–E) The expression levels of inhibitory Siglecs on DCs from primary tumor samples of patients with non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), and colorectal cancer (CRC). Data are presented as mean ± SD.